7OZB

FGFR1 kinase domain (residues 458-765) with mutations C488A, C584S in complex with 38.


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.71 Å
  • R-Value Free: 0.244 
  • R-Value Work: 0.209 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history


Literature

From Fragment to Lead: De Novo Design and Development toward a Selective FGFR2 Inhibitor.

Turner, L.D.Trinh, C.H.Hubball, R.A.Orritt, K.M.Lin, C.C.Burns, J.E.Knowles, M.A.Fishwick, C.W.G.

(2022) J Med Chem 65: 1481-1504

  • DOI: https://doi.org/10.1021/acs.jmedchem.1c01163
  • Primary Citation of Related Structures:  
    7OZB, 7OZD, 7OZF, 7OZY

  • PubMed Abstract: 

    Fibroblast growth factor receptors (FGFRs) are implicated in a range of cancers with several pan-kinase and selective-FGFR inhibitors currently being evaluated in clinical trials. Pan-FGFR inhibitors often cause toxic side effects and few examples of subtype-selective inhibitors exist. Herein, we describe a structure-guided approach toward the development of a selective FGFR2 inhibitor. De novo design was carried out on an existing fragment series to yield compounds predicted to improve potency against the FGFRs. Subsequent iterative rounds of synthesis and biological evaluation led to an inhibitor with nanomolar potency that exhibited moderate selectivity for FGFR2 over FGFR1/3. Subtle changes to the lead inhibitor resulted in a complete loss of selectivity for FGFR2. X-ray crystallographic studies revealed inhibitor-specific morphological differences in the P-loop which were posited to be fundamental to the selectivity of these compounds. Additional docking studies have predicted an FGFR2-selective H-bond which could be utilized to design more selective FGFR2 inhibitors.


  • Organizational Affiliation

    School of Chemistry, University of Leeds, Leeds, LS2 9JT, U.K.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Fibroblast growth factor receptor 1A [auth AAA],
B [auth BBB]
309Homo sapiensMutation(s): 2 
Gene Names: FGFR1BFGFRCEKFGFBRFLGFLT2HBGFR
EC: 2.7.10.1
UniProt & NIH Common Fund Data Resources
Find proteins for P11362 (Homo sapiens)
Explore P11362 
Go to UniProtKB:  P11362
PHAROS:  P11362
GTEx:  ENSG00000077782 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP11362
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 3 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
47I (Subject of Investigation/LOI)
Query on 47I

Download Ideal Coordinates CCD File 
C [auth AAA],
I [auth BBB]
4-[3-(4-piperazin-4-ium-1-ylphenyl)-1H-indazol-6-yl]phenol
C23 H23 N4 O
OYKIIJTXTXJYKZ-UHFFFAOYSA-O
SO4
Query on SO4

Download Ideal Coordinates CCD File 
D [auth AAA],
E [auth AAA],
J [auth BBB],
P [auth BBB],
Q [auth BBB]
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
EDO
Query on EDO

Download Ideal Coordinates CCD File 
F [auth AAA]
G [auth AAA]
H [auth AAA]
K [auth BBB]
L [auth BBB]
F [auth AAA],
G [auth AAA],
H [auth AAA],
K [auth BBB],
L [auth BBB],
M [auth BBB],
N [auth BBB],
O [auth BBB]
1,2-ETHANEDIOL
C2 H6 O2
LYCAIKOWRPUZTN-UHFFFAOYSA-N
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.71 Å
  • R-Value Free: 0.244 
  • R-Value Work: 0.209 
  • Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 206.26α = 90
b = 57.56β = 107.22
c = 65.79γ = 90
Software Package:
Software NamePurpose
xia2data reduction
Aimlessdata scaling
PHASERphasing
REFMACrefinement

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Medical Research Council (MRC, United Kingdom)United KingdomMR/K501402/1

Revision History  (Full details and data files)

  • Version 1.0: 2021-12-01
    Type: Initial release
  • Version 1.1: 2022-02-09
    Changes: Database references
  • Version 1.2: 2024-01-31
    Changes: Data collection, Derived calculations, Refinement description